AI-generated · cited to primary sources · not investment advice · How we research
Aurobindo Pharma
Our verdict on Aurobindo Pharma isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company confirmed that Dazublys (trastuzumab biosimilar) received marketing authorization from the European Commission. (3 met, 1 revised, 1 in progress across 5 tracked commitments)
“BP16 (Prolia biosimilar) met Phase 3 endpoints in a clinical study across 5 European countries, ready for regulatory submission in the next Quarter.”
The company generated $118 million in free cash flows during Q3FY26, exceeding the $100 million quarterly target. (2 exceeded, 2 missed, 1 met across 5 tracked commitments)
“Last but not least, we are confident of achieving our internal margin target of 20%-21% for FY26, as communicated earlier.”
See the full cited Management analysis of Aurobindo Pharma
How durable is the business?
The biosimilar moat is expanding significantly with multiple European Commission approvals and a clear timeline for US FDA submissions in FY26. (5 expanding)
“CuraTeQ Biologics – Building a global biosimilars company... A diversified portfolio of 15 products is positioned to drive and sustain CuraTeQ’s growth trajectory through 2030 and beyond”
Europe continues to be a high-growth geography, expanding its revenue share through strong performance across all key markets. (5 expanding across 1 engine)
“Europe: 2,703 [Cr]... Y-o-Y (%): 27.4%”
See the full cited Business Model analysis of Aurobindo Pharma
Where does growth come from?
The US market is showing accelerating momentum with revenue jumping 10.9% quarter-on-quarter to $470 Mn in Q4FY25, supported by 5 new product launches and 9 new filings in the quarter. (3 accelerating, 2 steady across 5 signals)
“US market: Received approval for 7 products and Launched 9 products”
The Pen-G project has hit a temporary reversal due to a fire incident and pending regulatory renewals, delaying the expected transition to profitability. (1 reversing, 2 new trend, 1 accelerating across 4 signals, 1 leading indicator)
“Based on our current production level, we expect to produce more than 10,000 metric tonnes on annualised basis over the next 12 months. It is important to note that the yield levels are steady and improving consistently over time.”
See the full cited Future Growth analysis of Aurobindo Pharma
What could break the thesis?
STABLE. The company still has a massive pipeline under review (142 ANDAs), but continues to receive approvals (5 in Q4) and file new applications (9 in Q4), maintaining high visibility for future launches. (4 stable, 1 intensifying, 1 high-severity)
“US ANDA Filings Snapshot as on 31st December 2025... Under Review 129”
The risk remains high as Eugia-3 remediation is still ongoing and the facility has not yet been cleared by the FDA. Management expects growth to be 'muted' in FY26 as a result of these disruptions. (4 stable, 1 high-severity)
“Sir, with respect to Eugia III inspection, if you could share some color in terms of the nature of observations... But ultimately, US FDA has to take a decision in terms of the warning letters. So, I cannot comment on what exactly they will do”
See the full cited Risk analysis of Aurobindo Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.